AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023
Eli Lilly deal validates MorphomerTM platform
Initiation of second Phase 2 trial of Tau antibody by partner Genentech
Multiple other products progressing, key appointments made to executive team
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on pioneering precision medicine in neuro- degenerative diseases, today announced financial results for the year ended December 31, 2018, and provided a business and clinical update detailing its corporate progress and anticipated milestones.